CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF431 (ImmuneEditome ID:170959)

1. Gene summary of enriched editing regions for ZNF431

check button Gene summary
Gene informationGene symbol

ZNF431

Gene ID

170959

GeneSynonymsZFP932
GeneCytomap

19p12

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 431
GeneModificationdate20230329
UniprotIDQ8TF32;M0QZN7;M0R1H8;M0QXY3;M0QZG4;A0A024R7Q8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:21144178-21148210:+ENST00000311048.10ENSG00000196705.7ZNF431intronicMIR3,MER92B,AluSx1,AluY,PABL_A-int,MER41A,AluSx3,AluSg,AluSq2chr19:21144178-21148210:+.alignment
chr19:21144178-21148210:+ENST00000594425.4ENSG00000196705.7ZNF431intronicMIR3,MER92B,AluSx1,AluY,PABL_A-int,MER41A,AluSx3,AluSg,AluSq2chr19:21144178-21148210:+.alignment
chr19:21144178-21148210:+ENST00000598331.1ENSG00000196705.7ZNF431intronicMIR3,MER92B,AluSx1,AluY,PABL_A-int,MER41A,AluSx3,AluSg,AluSq2chr19:21144178-21148210:+.alignment
chr19:21144178-21148210:+ENST00000599296.4ENSG00000196705.7ZNF431intronicMIR3,MER92B,AluSx1,AluY,PABL_A-int,MER41A,AluSx3,AluSg,AluSq2chr19:21144178-21148210:+.alignment
chr19:21144178-21148210:+ENST00000600692.4ENSG00000196705.7ZNF431intronicMIR3,MER92B,AluSx1,AluY,PABL_A-int,MER41A,AluSx3,AluSg,AluSq2chr19:21144178-21148210:+.alignment
chr19:21172155-21172799:+ENST00000311048.10ENSG00000196705.7ZNF431intronicL1MB2,AluJo,AluSzchr19:21172155-21172799:+.alignment
chr19:21172155-21172799:+ENST00000594425.4ENSG00000196705.7ZNF431intronicL1MB2,AluJo,AluSzchr19:21172155-21172799:+.alignment
chr19:21172155-21172799:+ENST00000598331.1ENSG00000196705.7ZNF431intronicL1MB2,AluJo,AluSzchr19:21172155-21172799:+.alignment
chr19:21172155-21172799:+ENST00000599296.4ENSG00000196705.7ZNF431intronicL1MB2,AluJo,AluSzchr19:21172155-21172799:+.alignment
chr19:21172155-21172799:+ENST00000600692.4ENSG00000196705.7ZNF431intronicL1MB2,AluJo,AluSzchr19:21172155-21172799:+.alignment
chr19:21180638-21180916:+ENST00000311048.10ENSG00000196705.7ZNF431intronicL1MB2,AluScchr19:21180638-21180916:+.alignment
chr19:21180638-21180916:+ENST00000594425.4ENSG00000196705.7ZNF431intronicL1MB2,AluScchr19:21180638-21180916:+.alignment
chr19:21180638-21180916:+ENST00000598331.1ENSG00000196705.7ZNF431intronicL1MB2,AluScchr19:21180638-21180916:+.alignment
chr19:21180638-21180916:+ENST00000599296.4ENSG00000196705.7ZNF431intronicL1MB2,AluScchr19:21180638-21180916:+.alignment
chr19:21180638-21180916:+ENST00000600692.4ENSG00000196705.7ZNF431intronicL1MB2,AluScchr19:21180638-21180916:+.alignment
chr19:21184125-21184344:+ENST00000311048.10ENSG00000196705.7ZNF431UTR3AluScchr19:21184125-21184344:+.alignment
chr19:21185481-21186302:+ENST00000594821.1ENSG00000196705.7ZNF431ncRNA_exonicAluSq2,AluSz,L1MA2chr19:21185481-21186302:+.alignment
chr19:21187232-21193517:+ENST00000594425.4ENSG00000196705.7ZNF431exonicAluSp,AluSq,AluSx1,L1P4,AluSz6,AluSx3,AluSx,L1MA8,AluSgchr19:21187232-21193517:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF431


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000196705.7,ZNF431HNSCEAG1.4883e-04image
chr19:21187232-21193517:+KICHEER6.9988e-03image
ENSG00000196705.7,ZNF431KICHEAG2.4287e-03image
chr19:21187232-21193517:+KIRCEER1.3473e-02image
chr19:21187232-21193517:+LUSCEER1.1185e-02image
chr19:21185481-21186302:+THCAEER6.4683e-10image
ENSG00000196705.7,ZNF431THCAEAG5.7092e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:21184125-21184344:+CESCEER1.8177e-021.5404e-026.4152e+03image
chr19:21187232-21193517:+CHOLEER1.3225e-021.5091e-028.9309e+09image
ENSG00000196705.7,ZNF431LGGEAG1.2760e-021.6262e-021.2242e-02image

Top

3. Enriched editing regions and immune related genes for ZNF431


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:21185481-21186302:+ESCAEERENSG00000196705,ZNF431-0.48797.5540e-051.2517e-08-0.4737imageNNNANK_cells_restingGSVA_HALLMARK_GLYCOLYSIS
chr19:21187232-21193517:+LAMLEERENSG00000222635,RNU6-1203P0.37503.2543e-021.2092e-060.4198imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr19:21187232-21193517:+LAMLEERENSG00000256745,RP11-680H20.10.36304.4777e-022.3344e-060.4095imageNNNAMonocytesGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr19:21187232-21193517:+THYMEERENSG00000013392,RWDD2A-0.34111.3209e-021.1957e-04-0.4030imageNNNAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_DN
chr19:21187232-21193517:+THYMEERENSG00000214725,CDIPT-AS10.31812.6182e-025.3669e-050.4213imageNNNADendritic_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:21187232-21193517:+THYMEERENSG00000105298,CACTIN0.28014.6849e-024.2432e-050.4264imageNNNADendritic_cells_restingGSVA_HALLMARK_P53_PATHWAY

More results



Top

4. Enriched editing regions and immune related splicing for ZNF431


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000196705.7,ZNF431
TGCTEAGIRENSG00000164896.15chr7151076623:151076832:151077100:1510771380.42302.2386e-042.4918e-070.4101imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184FASTKT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000196705.7,ZNF431
TGCTEAGESENSG00000164896.15chr7151076715:151076832:151076912:151077027:151077100:1510771380.42042.5309e-043.0984e-070.4071imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184FASTKT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr19:21187232-21193517:+
TGCTEERMEXENSG00000129657.10chr1777213917:77215753:77215792:77216114:77216205:77216257:77216283:77216296-0.26393.2361e-021.1683e-05-0.4134imageNNNA
ENSG00000196705.7,ZNF431
TGCTEAGIRENSG00000167721.6chr172322502:2324829:2325303:23254200.38421.2689e-031.2407e-080.4497imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000196705.7,ZNF431
TGCTEAGESENSG00000093167.13chr337083644:37083806:37091466:37091538:37094791:370949080.33578.8012e-034.8973e-070.4046imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184LRRFIP2B_cells_naiveGSVA_HALLMARK_MYC_TARGETS_V2
chr19:21187232-21193517:+
TGCTEERIRENSG00000016864.12chr352694488:52695554:52695927:52696040-0.33222.1460e-037.9576e-06-0.4064imageNNNAMonocytesGSVA_HALLMARK_HEDGEHOG_SIGNALING
ENSG00000196705.7,ZNF431
THYMEAGESENSG00000142733.10chr127355390:27355469:27355668:27355745:27356025:27356079-0.37851.5275e-024.6307e-06-0.4229imageNADAR;AIFM1;AUH;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;YWHAG;ZNF184NADendritic_cells_restingGSVA_HALLMARK_APOPTOSIS
chr19:21187232-21193517:+
THYMEERA3ENSG00000142733.10chr127356025:27356079:27355185:27355469:27355185:273557450.40752.2293e-022.3025e-060.4843imageNNNADendritic_cells_restingGSVA_HALLMARK_APOPTOSIS
chr19:21187232-21193517:+
THYMEERMEXENSG00000160932.6chr8143018556:143018586:143018832:143019119:143020257:143020377:143020887:1430209910.43336.9329e-032.8036e-060.4966imageNNLY6EGSVA_HALLMARK_PEROXISOME
ENSG00000196705.7,ZNF431
THYMEAGIRENSG00000141380.9chr1826035004:26035127:26035830:26035923-0.30732.1185e-028.6694e-05-0.4221imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184SS18T_cells_CD4_memory_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION

More results



Top

5. Enriched editing regions and immune infiltration for ZNF431


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:21187232-21193517:+ACCEERDendritic_cells_resting1.3928e-040.5726image
chr19:21184125-21184344:+BLCAEERDendritic_cells_activated1.2576e-02-0.2082image
chr19:21187232-21193517:+BLCAEERT_cells_follicular_helper9.0660e-030.1671image
ENSG00000196705.7,ZNF431BLCAEAGDendritic_cells_activated3.2280e-03-0.1681image
chr19:21185481-21186302:+BRCAEERDendritic_cells_resting2.8034e-020.0882image
chr19:21187232-21193517:+BRCAEERMast_cells_resting7.9267e-030.0903image
ENSG00000196705.7,ZNF431BRCAEAGNK_cells_activated8.4335e-050.1261image
chr19:21187232-21193517:+CESCEERT_cells_CD4_memory_resting2.2068e-020.1715image
ENSG00000196705.7,ZNF431CESCEAGPlasma_cells4.4925e-030.1967image
ENSG00000196705.7,ZNF431CHOLEAGMacrophages_M14.4082e-020.3904image
chr19:21187232-21193517:+COADEERMast_cells_activated3.3263e-020.1891image
ENSG00000196705.7,ZNF431COADEAGMast_cells_activated8.7644e-040.2638image
chr19:21172155-21172799:+ESCAEERT_cells_gamma_delta5.1814e-030.3933image
chr19:21187232-21193517:+ESCAEERT_cells_gamma_delta1.3021e-02-0.2094image
ENSG00000196705.7,ZNF431ESCAEAGNK_cells_resting1.1088e-02-0.2035image
chr19:21184125-21184344:+GBMEERMonocytes1.9337e-030.2978image
chr19:21184125-21184344:+HNSCEERB_cells_naive2.2957e-02-0.1797image
ENSG00000196705.7,ZNF431HNSCEAGT_cells_CD4_memory_activated2.4106e-020.1273image
chr19:21184125-21184344:+KICHEERDendritic_cells_activated4.9215e-02-0.3622image
chr19:21187232-21193517:+KICHEERT_cells_CD4_memory_activated1.9183e-020.3178image
ENSG00000196705.7,ZNF431KICHEAGNK_cells_activated3.6079e-02-0.2759image
ENSG00000196705.7,ZNF431KIRCEAGT_cells_CD81.7994e-020.1514image
chr19:21187232-21193517:+KIRPEERT_cells_CD82.1131e-03-0.3347image
chr19:21144178-21148210:+LAMLEERDendritic_cells_resting8.0852e-030.2960image
chr19:21187232-21193517:+LAMLEERMacrophages_M23.7112e-02-0.1874image
ENSG00000196705.7,ZNF431LAMLEAGDendritic_cells_resting3.6979e-020.1784image
chr19:21184125-21184344:+LGGEERT_cells_regulatory_(Tregs)1.3242e-030.2212image
chr19:21187232-21193517:+LGGEERMacrophages_M06.0664e-03-0.1259image
ENSG00000196705.7,ZNF431LGGEAGMacrophages_M01.0394e-02-0.1166image
ENSG00000196705.7,ZNF431LIHCEAGT_cells_CD4_naive2.3333e-040.5223image
chr19:21187232-21193517:+LUADEERPlasma_cells6.4029e-050.2195image
ENSG00000196705.7,ZNF431LUADEAGPlasma_cells3.1620e-030.1516image
ENSG00000196705.7,ZNF431LUSCEAGEosinophils4.8539e-02-0.1036image
chr19:21187232-21193517:+MESOEERT_cells_CD82.8058e-020.3108image
ENSG00000196705.7,ZNF431MESOEAGB_cells_naive1.1488e-02-0.3269image
chr19:21144178-21148210:+OVEERNK_cells_resting3.4820e-040.5565image
chr19:21185481-21186302:+OVEERT_cells_CD4_memory_activated6.8239e-030.2044image
chr19:21187232-21193517:+OVEERMacrophages_M28.1864e-030.1686image
ENSG00000196705.7,ZNF431OVEAGEosinophils6.2652e-040.2039image
ENSG00000196705.7,ZNF431PAADEAGNK_cells_activated2.1993e-020.2202image
chr19:21187232-21193517:+PCPGEERNK_cells_activated1.7213e-020.2708image
ENSG00000196705.7,ZNF431PCPGEAGNK_cells_activated4.1586e-020.2229image
chr19:21184125-21184344:+PRADEERT_cells_CD83.8014e-030.1885image
chr19:21187232-21193517:+PRADEERMast_cells_resting2.3974e-02-0.1286image
ENSG00000196705.7,ZNF431PRADEAGT_cells_follicular_helper1.0450e-02-0.1290image
chr19:21187232-21193517:+SARCEERNeutrophils2.6300e-02-0.1987image
ENSG00000196705.7,ZNF431SKCMEAGNK_cells_activated4.4863e-020.1389image
chr19:21144178-21148210:+STADEERMonocytes1.7496e-020.2396image
chr19:21185481-21186302:+STADEERMonocytes2.0184e-02-0.1735image
chr19:21187232-21193517:+STADEERT_cells_CD82.6454e-020.1390image
ENSG00000196705.7,ZNF431STADEAGT_cells_CD82.1345e-030.1708image
chr19:21184125-21184344:+TGCTEERB_cells_memory3.0955e-020.2887image
ENSG00000196705.7,ZNF431TGCTEAGT_cells_regulatory_(Tregs)1.5585e-020.1992image
chr19:21184125-21184344:+THCAEERMonocytes1.1540e-060.2721image
chr19:21185481-21186302:+THCAEERMacrophages_M01.2164e-03-0.1564image
chr19:21187232-21193517:+THCAEERMacrophages_M24.2640e-020.0926image
ENSG00000196705.7,ZNF431THCAEAGMacrophages_M25.3578e-030.1252image
chr19:21187232-21193517:+THYMEERT_cells_CD4_memory_activated4.1854e-02-0.2200image
ENSG00000196705.7,ZNF431THYMEAGT_cells_CD4_memory_activated2.5048e-02-0.2146image
chr19:21184125-21184344:+UCECEERNeutrophils2.7591e-020.3484image
chr19:21187232-21193517:+UCSEERMast_cells_resting4.6820e-020.3049image
ENSG00000196705.7,ZNF431UCSEAGNK_cells_resting6.2391e-030.3780image


Top

6. Enriched editing regions and immune gene sets for ZNF431


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:21187232-21193517:+ACCGSVA_HALLMARK_PROTEIN_SECRETIONEER3.6825e-020.3355image
ENSG00000196705.7,ZNF431ACCGSVA_HALLMARK_GLYCOLYSISEAG7.4232e-030.3637image
chr19:21184125-21184344:+BLCAGSVA_HALLMARK_GLYCOLYSISEER9.3569e-050.3208image
ENSG00000196705.7,ZNF431BLCAGSVA_HALLMARK_APICAL_JUNCTIONEAG1.4200e-030.1819image
chr19:21187232-21193517:+BLCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEER4.5004e-03-0.1816image
ENSG00000196705.7,ZNF431BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG9.4153e-080.1706image
chr19:21185481-21186302:+BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.2954e-060.1817image
chr19:21187232-21193517:+BRCAGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.0979e-050.1490image
chr19:21184125-21184344:+CESCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.8472e-040.3672image
chr19:21187232-21193517:+CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.9283e-02-0.1634image
ENSG00000196705.7,ZNF431CESCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG4.3855e-03-0.1973image
chr19:21187232-21193517:+CHOLGSVA_HALLMARK_UV_RESPONSE_DNEER2.0040e-040.7000image
ENSG00000196705.7,ZNF431CHOLGSVA_HALLMARK_DNA_REPAIREAG1.9532e-03-0.5690image
chr19:21187232-21193517:+ESCAGSVA_HALLMARK_APICAL_JUNCTIONEER6.5261e-03-0.2289image
chr19:21185481-21186302:+ESCAGSVA_HALLMARK_ANGIOGENESISEER1.2670e-030.2797image
ENSG00000196705.7,ZNF431ESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.7034e-02-0.1677image
chr19:21172155-21172799:+ESCAGSVA_HALLMARK_SPERMATOGENESISEER3.8601e-020.2965image
chr19:21184125-21184344:+GBMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2204e-06-0.4510image
ENSG00000196705.7,ZNF431GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.3552e-040.2884image
chr19:21187232-21193517:+GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.1414e-030.2712image
chr19:21185481-21186302:+GBMGSVA_HALLMARK_COAGULATIONEER5.9777e-070.4749image
chr19:21184125-21184344:+HNSCGSVA_HALLMARK_GLYCOLYSISEER3.1337e-030.2322image
chr19:21187232-21193517:+HNSCGSVA_HALLMARK_PROTEIN_SECRETIONEER5.6779e-03-0.1811image
ENSG00000196705.7,ZNF431HNSCGSVA_HALLMARK_UV_RESPONSE_DNEAG3.3741e-04-0.2010image
ENSG00000196705.7,ZNF431KICHGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.9630e-030.3727image
chr19:21184125-21184344:+KICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.1656e-03-0.5209image
chr19:21187232-21193517:+KICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.6986e-03-0.3885image
chr19:21184125-21184344:+KIRCGSVA_HALLMARK_COAGULATIONEER1.2411e-050.3359image
chr19:21187232-21193517:+KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.4515e-020.1776image
ENSG00000196705.7,ZNF431KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.0509e-030.1721image
chr19:21187232-21193517:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER4.7826e-020.2192image
chr19:21144178-21148210:+LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER7.2486e-030.2999image
chr19:21187232-21193517:+LAMLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.6056e-030.2474image
ENSG00000196705.7,ZNF431LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0852e-12-0.3167image
chr19:21184125-21184344:+LGGGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.5353e-080.3639image
chr19:21187232-21193517:+LGGGSVA_HALLMARK_MYOGENESISEER1.3288e-100.2895image
ENSG00000196705.7,ZNF431LIHCGSVA_HALLMARK_SPERMATOGENESISEAG1.5368e-02-0.3592image
ENSG00000196705.7,ZNF431LUADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.0012e-030.1587image
chr19:21187232-21193517:+LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.0522e-03-0.1490image
chr19:21185481-21186302:+LUADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.2079e-040.2412image
ENSG00000196705.7,ZNF431LUSCGSVA_HALLMARK_UV_RESPONSE_UPEAG2.2883e-02-0.1194image
chr19:21187232-21193517:+LUSCGSVA_HALLMARK_SPERMATOGENESISEER7.9488e-030.1468image
chr19:21185481-21186302:+OVGSVA_HALLMARK_MITOTIC_SPINDLEEER5.4149e-03-0.2100image
ENSG00000196705.7,ZNF431OVGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4682e-04-0.2258image
chr19:21187232-21193517:+OVGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER8.7081e-030.1673image
chr19:21144178-21148210:+OVGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.5949e-02-0.3302image
chr19:21187232-21193517:+PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.6284e-020.2730image
ENSG00000196705.7,ZNF431PCPGGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.3240e-030.3447image
chr19:21184125-21184344:+PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER2.5490e-08-0.3541image
ENSG00000196705.7,ZNF431PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.2249e-04-0.1719image
chr19:21187232-21193517:+PRADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER4.2742e-020.1155image
ENSG00000196705.7,ZNF431READGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.6122e-020.3121image
chr19:21187232-21193517:+SARCGSVA_HALLMARK_UV_RESPONSE_DNEER3.5012e-030.2593image
ENSG00000196705.7,ZNF431SARCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.8203e-020.1741image
ENSG00000196705.7,ZNF431SKCMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.0477e-020.1767image
chr19:21144178-21148210:+STADGSVA_HALLMARK_MYOGENESISEER8.5251e-050.3863image
chr19:21187232-21193517:+STADGSVA_HALLMARK_MYOGENESISEER4.8741e-020.1236image
chr19:21185481-21186302:+STADGSVA_HALLMARK_ANGIOGENESISEER2.4605e-020.1680image
ENSG00000196705.7,ZNF431STADGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.6022e-07-0.2794image
ENSG00000196705.7,ZNF431TGCTGSVA_HALLMARK_E2F_TARGETSEAG8.8278e-06-0.3574image
chr19:21184125-21184344:+TGCTGSVA_HALLMARK_COAGULATIONEER8.3352e-040.4340image
chr19:21185481-21186302:+THCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.6507e-03-0.1522image
ENSG00000196705.7,ZNF431THCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.7582e-070.2326image
chr19:21144178-21148210:+THCAGSVA_HALLMARK_PEROXISOMEEER7.5264e-030.5214image
chr19:21187232-21193517:+THCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.3749e-060.2134image
chr19:21184125-21184344:+THCAGSVA_HALLMARK_UV_RESPONSE_DNEER9.6056e-05-0.2197image
ENSG00000196705.7,ZNF431THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.5018e-030.3004image
chr19:21187232-21193517:+THYMGSVA_HALLMARK_KRAS_SIGNALING_UPEER1.0141e-02-0.2759image
chr19:21185481-21186302:+UCECGSVA_HALLMARK_G2M_CHECKPOINTEER1.2564e-02-0.3128image
chr19:21184125-21184344:+UCECGSVA_HALLMARK_PANCREAS_BETA_CELLSEER4.9911e-020.3121image
ENSG00000196705.7,ZNF431UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.0128e-02-0.1903image
ENSG00000196705.7,ZNF431UCSGSVA_HALLMARK_DNA_REPAIREAG8.0847e-030.3669image


Top

7. Enriched editing regions and drugs for ZNF431


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr19:21187232-21193517:+ACCBMS.536924EER3.3994e-020.3404image
ENSG00000196705.7,ZNF431ACCJNK.Inhibitor.VIIIEAG2.9923e-03-0.4001image
chr19:21184125-21184344:+BLCACGP.60474EER5.9779e-04-0.2836image
ENSG00000196705.7,ZNF431BLCAFH535EAG8.4685e-040.1901image
ENSG00000196705.7,ZNF431BRCABryostatin.1EAG3.8263e-07-0.1625image
chr19:21187232-21193517:+BRCAEtoposideEER1.9512e-030.1052image
chr19:21185481-21186302:+BRCAGNF.2EER1.1557e-07-0.2109image
chr19:21184125-21184344:+CESCGDC.0449EER6.1251e-04-0.3384image
chr19:21187232-21193517:+CESCAZD8055EER2.0020e-03-0.2301image
ENSG00000196705.7,ZNF431CESCGDC.0449EAG4.2077e-04-0.2429image
ENSG00000196705.7,ZNF431CHOLAZD6482EAG3.1672e-03-0.5468image
chr19:21187232-21193517:+CHOLAZD6482EER1.0566e-03-0.6379image
ENSG00000196705.7,ZNF431COADGW843682XEAG3.5191e-050.3248image
chr19:21187232-21193517:+COADGW843682XEER6.5614e-040.2984image
chr19:21187232-21193517:+ESCAAICAREER5.5462e-030.2332image
ENSG00000196705.7,ZNF431ESCAGDC.0449EAG1.8103e-04-0.2973image
chr19:21185481-21186302:+ESCAGDC.0449EER1.4271e-04-0.3287image
chr19:21144178-21148210:+ESCABicalutamideEER4.0996e-02-0.2603image
chr19:21172155-21172799:+ESCABIBW2992EER1.7186e-020.3390image
chr19:21187232-21193517:+GBMBI.D1870EER7.1463e-040.2817image
chr19:21185481-21186302:+GBMBI.D1870EER5.4598e-070.4763image
ENSG00000196705.7,ZNF431GBMLenalidomideEAG1.9609e-040.3045image
chr19:21184125-21184344:+GBMBAY.61.3606EER3.9488e-080.5028image
chr19:21187232-21193517:+HNSCMethotrexateEER1.4470e-02-0.1604image
chr19:21184125-21184344:+HNSCAKT.inhibitor.VIIIEER5.1356e-040.2716image
ENSG00000196705.7,ZNF431HNSCCEP.701EAG2.7763e-05-0.2341image
chr19:21184125-21184344:+KICHEmbelinEER4.5394e-040.6002image
ENSG00000196705.7,ZNF431KICHBMS.708163EAG5.7721e-040.4384image
chr19:21187232-21193517:+KICHAP.24534EER2.5603e-02-0.3036image
chr19:21187232-21193517:+KIRCEmbelinEER4.3778e-02-0.1468image
chr19:21184125-21184344:+KIRCA.770041EER3.1035e-05-0.3211image
ENSG00000196705.7,ZNF431KIRCGSK269962AEAG4.2529e-04-0.2239image
chr19:21187232-21193517:+KIRPBMS.509744EER8.3269e-030.2895image
chr19:21144178-21148210:+LAMLAZD6482EER2.1651e-03-0.3401image
chr19:21187232-21193517:+LAMLBMS.708163EER2.7229e-02-0.1983image
ENSG00000196705.7,ZNF431LAMLBMS.708163EAG1.3504e-03-0.2712image
ENSG00000196705.7,ZNF431LGGEmbelinEAG2.0333e-100.2844image
chr19:21187232-21193517:+LGGCamptothecinEER1.5981e-070.2379image
chr19:21184125-21184344:+LGGEmbelinEER4.6366e-060.3115image
ENSG00000196705.7,ZNF431LIHCFTI.277EAG3.3142e-03-0.4285image
chr19:21187232-21193517:+LUADGefitinibEER9.9777e-040.1817image
ENSG00000196705.7,ZNF431LUADCEP.701EAG3.0830e-03-0.1520image
chr19:21185481-21186302:+LUADBMS.509744EER4.2624e-03-0.1805image
ENSG00000196705.7,ZNF431LUSCGDC.0449EAG3.2375e-03-0.1541image
chr19:21187232-21193517:+LUSCBicalutamideEER8.7181e-030.1451image
ENSG00000196705.7,ZNF431MESOAZD7762EAG7.0384e-04-0.4288image
chr19:21144178-21148210:+OVJW.7.52.1EER2.3377e-040.5696image
chr19:21187232-21193517:+OVBAY.61.3606EER7.7796e-04-0.2133image
ENSG00000196705.7,ZNF431OVBleomycinEAG1.0360e-05-0.2610image
chr19:21185481-21186302:+OVErlotinibEER2.7282e-05-0.3123image
ENSG00000196705.7,ZNF431PAADAZ628EAG1.1351e-02-0.2462image
ENSG00000196705.7,ZNF431PCPGElesclomolEAG2.0535e-03-0.3317image
chr19:21187232-21193517:+PCPGCCT018159EER1.8431e-030.3494image
chr19:21184125-21184344:+PRADAZ628EER7.3520e-06-0.2884image
chr19:21187232-21193517:+PRADBMS.708163EER1.0558e-03-0.1857image
ENSG00000196705.7,ZNF431PRADBMS.754807EAG9.8734e-04-0.1655image
ENSG00000196705.7,ZNF431SARCABT.263EAG1.3213e-02-0.1962image
chr19:21187232-21193517:+SARCAZD6482EER3.4052e-03-0.2600image
ENSG00000196705.7,ZNF431SKCMGNF.2EAG1.6353e-02-0.1659image
chr19:21144178-21148210:+STADEmbelinEER1.0054e-06-0.4707image
chr19:21187232-21193517:+STADGSK269962AEER2.1430e-04-0.2307image
chr19:21185481-21186302:+STADGDC.0449EER1.3494e-03-0.2378image
ENSG00000196705.7,ZNF431STADBMS.536924EAG3.6327e-03-0.1619image
chr19:21187232-21193517:+TGCTBryostatin.1EER4.7495e-03-0.2627image
chr19:21184125-21184344:+TGCTDasatinibEER1.5948e-04-0.4836image
ENSG00000196705.7,ZNF431TGCTDoxorubicinEAG1.6728e-060.3831image
ENSG00000196705.7,ZNF431THCAEpothilone.BEAG1.0950e-090.2701image
chr19:21144178-21148210:+THCABleomycinEER5.4331e-040.6418image
chr19:21184125-21184344:+THCAEtoposideEER1.8234e-090.3330image
chr19:21187232-21193517:+THCAEpothilone.BEER9.6710e-100.2744image
chr19:21185481-21186302:+THCAEpothilone.BEER4.0602e-070.2428image
chr19:21187232-21193517:+THYMJNK.9LEER1.2946e-080.5666image
ENSG00000196705.7,ZNF431THYMJNK.9LEAG1.5756e-070.4770image
chr19:21187232-21193517:+UCECJNK.9LEER2.1605e-030.2869image
chr19:21185481-21186302:+UCECMidostaurinEER7.9632e-040.4119image
chr19:21184125-21184344:+UCECBosutinibEER2.1129e-02-0.3635image
ENSG00000196705.7,ZNF431UCECJNK.9LEAG7.2204e-050.3409image
chr19:21187232-21193517:+UCSJNK.9LEER1.2230e-020.3789image
ENSG00000196705.7,ZNF431UCSMethotrexateEAG1.3998e-03-0.4356image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType